Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-08-22
2006-08-22
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S153100, C424S155100, C424S156100, C424S173100, C424S174100, C424S178100, C424S181100, C424S183100, C424S001490
Reexamination Certificate
active
07094404
ABSTRACT:
The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection.90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.
REFERENCES:
Rubin et al. Ann. Int. Med. 113: 619-627 (1990).
Waldmann et al. Blood 82 : 1701-1712, 1993.
Waldmann et al. Blood 86: 4063-4075 (1995).
Vriesendorp et al. Int. J. Radiation Oncology 22:37-45 (1991).
Kozak et al. PNAS 83:474-478 (1986).
Diamanstein et al. Immunol. Rev. 92:5-27(1986).
Order et al. Int. J. Radiat. Oncol. Biol. Phys 12: 277-281 (1986).
Wessels et al. Med Phys 11: 638-645(1984).
Waldmann Important Advances in Oncology 1994 Devita et al. (ED) J. B. Lippincott Co. Philadelphia.
Waldmann Leukemia 7 (Suppl. 2) S151-S156 (1993).
Hakimi et al. J. Immunol. 147: 1352-1359(1991).
Kreitman et al. Bioconjugate Chem. 4: 112-120(1993).
Parenteau et al. Transplantation 54: 963-968 (1992).
The Merck Manual of Diagnosis and Therapy 16thEdition Beretow et al., Eds., Merck Research Laboratories Rahway NJ 1992 pp. 2610-2617.
T.A. Waldmann, “Lymphokine Receptors: A Target For Immunotherapy of Lymphomas,”Annals of Oncology, vol. 5, pp. 13-17, 1994.
Paul S. Brown, Jr. et al., “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival,”Proc. Natl. Acad. Sc., vol. 88, pp. 2663-2667, Apr. 1991.
Robert J. Kreitman, et al., “The Recombinant Immunotoxin Anti-Tac (Fv)-Pseudomonas Exotoxin 40 is Cytotoxic Toward Peripheral Blood Malignant Cells From Patients with Adult T-Cells Leukemia,”Proc. Natl. Acad. Sci, vol. 87, pp. 8291-8295, Nov. 1990.
R.P. Junghans, et al., “ Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,”Cancer Research, vol. 50, pp. 1495-1502, Mar. 1, 1990.
Gambel Phillip
Leydig Voit & Mayer LTD
The United States of America as represented by the Department of
LandOfFree
Method for treating malignancy and autoimmune disorders in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating malignancy and autoimmune disorders in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating malignancy and autoimmune disorders in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631532